Pro Nephro AKI (NGAL) is now FDA-Cleared     READ MORE

Search

Aktieudbud 2020

BioPorto A/S udbyder nye aktier med fortegningsret for eksisterende aktionærer. Provenuet skal anvendes til at sikre godkendelse og forstærke udrulning af The NGAL Test samt accelerere udviklingen af nye diagnostiske tests.

Dokumenter

BioPorto har de seneste år gennemgået en markant udvikling og modning af sin teknologi, platforme og produkter. For at understøtte driften vil BioPorto styrke selskabets kapitalberedskab gennem et udbud af op til 66,6 millioner stk. nye aktier i en fortegningsemission rettet mod eksisterende aktionærer og med mulighed for nye investorer til at tegne med.

Du kan læse mere om udbuddet her:

Prospekt
Investor Brochure
Investor Præsentation

Videoer

Se administrerende direktør Peter Mørch Eriksen præsentere BioPortos strategi.

Se Chief Medical Officer Chris Bird præsentere BioPortos teknologi.

Se finansdirektør Ole Larsen præsentere BioPortos aktieemission.

Eksempel

En beholdning på 30 aktier i BioPorto giver 30 tegningsretter, som tildeles gratis den 29. september 2020. Der anvendes tre tegningsretter for hver ny aktie, der tegnes. Der kan således tegnes 10 nye aktier til tegningskursen på 1,60 kr. pr. ny aktie. Tegningsretter kan sælges på Nasdaq Copenhagen i perioden 28. september 2020 til 9. oktober 2020, eller der kan i samme periode tilkøbes flere tegningsretter for at kunne tegne yderligere nye aktier.

Vigtige datoer

En beholdning på 30 aktier i BioPorto giver 30 tegningsretter, som tildeles gratis den 29. september 2020. Der anvendes tre tegningsretter for hver ny aktie, der tegnes. Der kan således tegnes 10 nye aktier til tegningskursen på 1,60 kr. pr. ny aktie. Tegningsretter kan sælges på Nasdaq Copenhagen i perioden 28. september 2020 til 9. oktober 2020, eller der kan i samme periode tilkøbes flere tegningsretter for at kunne tegne yderligere nye aktier.

Spørgsmål og svar

Access to this information is limited to persons resident and physically present in Denmark and to authorized persons who are resident and physically present in jurisdiction outside the United States, Australia, Canada, Japan and any other Excluded Territories.

Disclaimer

All materials relating to the Offering, including the prospectus, all company announcements relating to the Offering and any other document relating to the Offering, should be accessible only behind the click-through, which should operate as described in the following. Only after pressing the “I accept”-button and satisfying the requirements the user should gain access to the materials behind the click-through.
1. The following text should be displayed on the first page before the user might gain access to the materials relating to the Offering:
ELECTRONIC VERSIONS OF MATERIAL REGARDING THE RIGHTS ISSUE OF BIOPORTO A/S (THE “COMPANY”) ARE BEING MADE AVAILABLE ON THIS WEBSITE IN GOOD FAITH BY THE COMPANY AND ARE FOR INFORMATION PURPOSES ONLY. BY ACCESSING THE DOCUMENT YOU ACKNOWLEDGE AND CONFIRM THE FOLLOWING.
Access to the information and documents contained on this website in relation to the contemplated rights issue by BioPorto A/S (the “Material”) may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons who wish to have access to information regarding the rights issue announced by the Company in company announcement 17 of 25 September 2020 and any future company announcement regarding the rights issue (the “Announcements”), should ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable laws and regulations by any person.
The information in the Material is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (“the United States”), Australia, Canada, Japan or any other jurisdiction where to do so would constitute a violation of the local securities laws and regulation of such jurisdiction (the “Excluded Territories”).
The shares as mentioned in the Material and the Announcements (the “Shares”) have not and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act or applicable state securities law. There will be no public offering of the Shares in the United States.
The Shares have not been and will not be registered under any applicable securities laws of any state, province, territory, county or jurisdiction of the Excluded Territories. Accordingly, such Shares may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the Excluded Territories or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such Shares in, the relevant jurisdiction. There will be no public offer of Shares in any Excluded Territory.
In relation to each member state of the European Economic Area where the Prospectus Regulation applies (each a “Relevant Member State”), no offering of Pre-emptive Rights or New Shares will be made to the public in any Relevant Member State prior to the publication of a prospectus concerning the Pre-emptive Rights and the New Shares which has been approved by the competent authority in such Relevant Member State or, where relevant, approved in another Relevant Member State and notified to the competent authority in such Relevant Member State, all pursuant to the Prospectus Regulation, except that an offering of Preemptive Rights and New Shares may be made to the public at any time in such Relevant Member State pursuant to the following exemptions from the Prospectus Regulation:
a) to any legal entity which is a qualified investor as defined in the Prospectus Regulation (“Qualified Investor”);
b) to fewer than 150 natural or legal persons other than Qualified Investors, subject to obtaining the prior written consent of the Company and its financial advisers; or
c) in any other circumstances falling within Article 1(4) of the Prospectus Regulation.
In any Relevant Member State other than Denmark, the Material is only addressed to, and is only directed at, shareholders and investors in such Relevant Member State that fulfil the criteria for exemption from the obligation to publish a prospectus, including Qualified Investors.
For the purposes of the above, the expression an “offer of Pre-emptive Rights and New Shares to the public” in relation to Pre-emptive Rights and New Shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the Offering, the Pre-emptive Rights and the New Shares so as to enable a shareholder and/or an investor to decide whether to acquire the Pre-emptive Rights and acquire or subscribe for the New Shares.
The Prospectus is only being distributed to, and is only directed at, and the information in the Material is only directed at and intended for, (i) persons outside the UK or (ii) “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order”) or (iii) “high net worth companies” and other persons to whom it may lawfully be communicated, falling within the meaning of Article 49(2)(a) to (d) of the Financial Promotion Order (all such persons being “Relevant Persons”). Pre-emptive Rights and New Shares are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Pre-emptive Rights or New Shares will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act on or rely upon the Material or any of its contents.
If you are not permitted to view the Material or are in doubt as to whether you are permitted to view the Material, please exit this webpage.
By proceeding, you will be deemed to have accepted and confirmed the following:
1. That you are not a resident of or located in the United States, Australia, Canada, Japan or any Excluded Territory and that you are physically present outside the United States, Australia, Canada, Japan or any Excluded Territory; and
2. You are a resident of and physically present (a) in Denmark or (b) outside Denmark and each of the jurisdictions referred to in clause (1) above and, in that case, you are authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.